Reuters: Company News: Merck's Keytruda sets new 5-year survival standard for advanced lung cancer

Reuters: Company News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals.

Merck's Keytruda sets new 5-year survival standard for advanced lung cancer Jun 1st 2019, 11:30 Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting on Saturday.

You are receiving this email because you subscribed to this feed at blogtrottr.com. By using Blogtrottr, you agree to our policies, terms and conditions. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions.